The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types
Open accessAbstract
Poly (ADP-ribose) polymerase-1 (PARP1) is a key facilitator of DNA repair and is implicated in pathways of tumorigenesis. PARP inhibitors have gained recent attention as rationally designed therapeutics for the treatment of several malignancies, particularly those associated with dysfunctional DNA repair pathways, including triple-negative breast cancer (TNBC). We investigated the PARP1 gene expression profile in surgical samples from more than 8,000 primary malignant and normal human tissues. PARP1 expression was found to be significantly increased in several malignant tissues, including those isolated from patients with breast, uterine, lung, ovarian, and skin cancers, and non-Hodgkin's lymphoma. Within breast infiltrating ductal carcinoma (IDC) samples tested, mean PARP1 expression was significantly higher relative to normal breast tissue, with over 30% of IDC samples demonstrating upregulation of PARP1, compared with 2.9% of normal tissues. Because of known DNA repair defects, including BRCA1 dysfunction, associated with TNBC, exploration of PARP1 expression in breast cancers related to expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) led to the observation that negative expression of any of the 3 receptors was associated with upregulation of PARP1 expression, compared with receptor-positive tissues. To validate these observations, an independent set of breast adenocarcinomas was evaluated and demonstrated >2-fold upregulation of PARP1 in approximately 70% of primary breast adenocarcinomas, including TNBC, compared with syngeneic nonmalignant breast tissues. Immunohistochemistry (IHC) showed that upregulation of the PARP1 gene was consistent with increased protein expression in TNBC. These analyses suggest a potential biological role for PARP1 in several distinct malignancies, including TNBC. Further investigation of PARP1 as a biomarker for the therapeutic activity of PARP inhibitor-based therapy is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
Hallmarks of 'BRCAness' in sporadic cancers
Turner, N., Tutt, A., & Ashworth, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1457 · Cited by 1,657
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Kinzler, K. W., & Vogelstein, B. (1997) · Nature · doi:10.1038/386761a0 · Cited by 1,240
Triple-negative breast cancer: therapeutic options
Cleator, S., Heller, W., & Coombes, R. C. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70074-8 · Cited by 882
Poly(ADP-ribosyl)ation by PARP-1: `PAR-laying' NAD+ into a nuclear signal
Kim, M. Y., Zhang, T., & Kraus, W. L. (2005) · Genes & Development · doi:10.1101/gad.1331805 · Cited by 802
Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer
van der Groep, P., Bouter, A., van der Zanden, R., Menko, F. H., Buerger, H., Verheijen, R. H. M., van der Wall, E., & van Diest, P. J. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh114 · Cited by 798
PARP-2, A Novel Mammalian DNA Damage-dependent Poly(ADP-ribose) Polymerase
Amé, J.-C., Rolli, V., Schreiber, V., Niedergang, C., Apiou, F., Decker, P., Muller, S., Höger, T., Murcia, J. M.-D., & de Murcia, G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.17860 · Cited by 745
Schreiber, V., Amé, J.-C., Dollé, P., Schultz, I., Rinaldi, B., Fraulob, V., Ménissier-de Murcia, J., & de Murcia, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202390200 · Cited by 705
The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability
Gudmundsdottir, K., & Ashworth, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209874 · Cited by 622
Lakhani, S. R., Reis-Filho, J. S., Fulford, L., Penault-Llorca, F., van der Vijver, M., Parry, S., Bishop, T., Benitez, J., Rivas, C., Bignon, Y.-J., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2424 · Cited by 611
BRCA1 dysfunction in sporadic basal-like breast cancer
Turner, N. C., Reis-Filho, J. S., Russell, A. M., Springall, R. J., Ryder, K., Steele, D., Savage, K., Gillett, C. E., Schmitt, F. C., Ashworth, A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210014 · Cited by 573
Glass, A. G., Lacey, J. V., Carreon, J. D., & Hoover, R. N. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm059 · Cited by 439
Genetic Predisposition to Breast Cancer: Past, Present, and Future
Turnbull, C., & Rahman, N. (2008) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.9.081307.164339 · Cited by 302
Dong, Y., Hakimi, M.-A., Chen, X., Kumaraswamy, E., Cooch, N. S., Godwin, A. K., & Shiekhattar, R. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00424-6 · Cited by 276
Hansel, D. E., Rahman, A., House, M., Ashfaq, R., Berg, K., Yeo, C. J., & Maitra, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0285 · Cited by 164
Alli, E., Sharma, V. B., Sunderesakumar, P., & Ford, J. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4016 · Cited by 156
A B-cell-specific DNA Recombination Complex
Borggrefe, T., Wabl, M. R., Akhmedov, A. T., & Jessberger, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.27.17025 · Cited by 155
CA 125 in Ovarian Cancer: Advances and Controversy
Fritsche, H. A., & Bast, R. C. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.7.1379 · Cited by 106
Interaction of the Transcription Factor YY1 with Human Poly(ADP-Ribosyl) Transferase
Oei, S. L., Griesenbeck, J., Schweiger, M., Babich, V., Kropotov, A., & Tomilin, N. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7621 · Cited by 102
Bürkle, A. (2001) · Cancer Letters · doi:10.1016/s0304-3835(00)00694-7 · Cited by 96
Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor
Soldatenkov, V. A., Albor, A., Patel, B. K. R., Dreszer, R., Dritschilo, A., & Notario, V. (1999) · Oncogene · doi:10.1038/sj.onc.1202778 · Cited by 90
Saxena, A. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.19.2319 · Cited by 86
Weberpals, J. I., Clark-Knowles, K. V., & Vanderhyden, B. C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3902 · Cited by 71
Enhancement of poly‐adenosine diphosphate‐ribosylation in human hepatocellular carcinoma
Nomura, F., Yaguchi, M., Togawa, A., Miyazaki, M., Isobe, K., Miyake, M., Noda, M., & Nakai, T. (2000) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.2000.02193.x · Cited by 67
Diagnosis of the Small Round Blue Cell Tumors Using Multiplex Polymerase Chain Reaction
Chen, Q., Vansant, G., Oades, K., Pickering, M., Wei, J. S., Song, Y., Monforte, J., & Khan, J. I. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060111 · Cited by 58
Ogura, T., Nyunoya, H., Takahashi-Masutani, M., Miwa, M., Sugimura, T., & Esumi, H. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(90)92082-b · Cited by 44
Basal-like subtype and BRCA1 dysfunction in breast cancers
Miyoshi, Y., Murase, K., & Oh, K. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0831-x · Cited by 39
Hereditary Factors in Gynecologic Cancer
Lynch, H. T., Casey, M. J., Shaw, T. G., & Lynch, J. F. (1998) · The Oncologist · doi:10.1634/theoncologist.3-5-319 · Cited by 39
Therapeutic options for triple-negative breast cancers with defective homologous recombination
Jaspers, J. E., Rottenberg, S., & Jonkers, J. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.07.001 · Cited by 38
Human poly(ADP‐ribose) polymerase gene
Yokoyama, Y., Kawamoto, T., Mitsuuchi, Y., Kurosaki, T., Toda, K., Ushiro, H., Terashima, M., Sumimoto, H., Kuribayashi, I., Yamamoto, Y., et al. (1990) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1990.tb15647.x · Cited by 32
Poly(ADP-ribose) Polymerase-1 Down-regulates BRCA2 Expression through the BRCA2 Promoter
Wang, J., Bian, C., Li, J., Couch, F. J., Wu, K., & Zhao, R. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803693200 · Cited by 32
Enhanced poly ADP-ribosylation in human leukemia lymphocytes and ovarian cancers
Singh, N. K. (1991) · Cancer Letters · doi:10.1016/0304-3835(91)90035-g · Cited by 22
Changes in NAD/ADP-ribose metabolism in rectal cancer
Yalçıntepe, L., Şener, L. T., Sener, A., Yetkın, G., Tiryaki, D., & Bermek, E. (2005) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2005000300006 · Cited by 18
Cited by
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
Morales, J., Li, L., Fattah, F. J., Dong, Y., Bey, E. A., Patel, M., Gao, J., & Boothman, D. A. (2014) · Critical Reviews in Eukaryotic Gene Expression · doi:10.1615/critreveukaryotgeneexpr.2013006875 · Cited by 608
microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis
Annese, T., Tamma, R., De Giorgis, M., & Ribatti, D. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.581007 · Cited by 288
Cisplatin Resistance Associated with PARP Hyperactivation
Michels, J., Vitale, I., Galluzzi, L., Adam, J., Olaussen, K. A., Kepp, O., Senovilla, L., Talhaoui, I., Guegan, J., Enot, D. P., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3000 · Cited by 176
PARP-1 protein expression in glioblastoma multiforme
Galia, A., Calogero, A. E., Condorelli, R., Fraggetta, F., La Corte, A., Ridolfo, F., Bosco, P., Castiglione, R., & Salemi, M. (2012) · European Journal of Histochemistry · doi:10.4081/ejh.2012.e9 · Cited by 145
Metadata
- Authors
- Ossovskaya, V., Koo, I. C., Kaldjian, E. P., Alvares, C., & Sherman, B. M.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2010-08-01
- Volume
- 1
- Issue
- 8
- Pages
- 812-821
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2145469049
- Cited by
- 269
- References
- 38
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.